Gain Therapeutics

GT Gain Therapeutics SA, established in 2017, is a developer of pharmacological chaperone drugs for the treatment of rare metabolic diseases. The company's drugs utilize Minoryx Direct Enzyme Therapy to identify a new generation of simple adjuvants, enabling customers to help stabilize misfolded mutations and restore the enzymatic activity of proteins in patients.